Table 1.
Patient characteristics according to whether they had multidrug-resistant P. aeruginosa isolates from respiratory tract samples.
| Characteristic | Non-MDR (n = 63) | MDR (n = 34) | p-value |
|---|---|---|---|
| Age (years, median (SD)) | 64.3 (18.5) | 69.6 (19.6) | 0.1929 |
| Gender | |||
| Male (n (%)) | 43 (68.3) | 21 (61.8) | 0.5198 |
| Female (n (%)) | 20 (31.7) | 13 (38.2) | |
| Etiology | |||
| Postinfectious origin | 18 (28.6) | 11 (32.4) | 0.6979 |
| Other originsa | 14 (22.2) | 5 (14.7) | 0.3735 |
| Idiopathicb | 31 (49.2) | 18 (52.9) | 0.7256 |
| Duration of PA infection (months, median (IQR)) | 20 (16–38) | 54 (21–451) | 0.0006 |
| Hospital-associated infection (n (%)) | 41 (65.1) | 16 (47.1) | 0.0854 |
| ICU stay (n (%)) | 36 (57.1) | 14 (41.2) | 0.1333 |
| VAP (n (%)) | 29 (46.0) | 14 (41.2) | 0.6460 |
| Prior antibiotic exposuresc | |||
| Fluoroquinolone (n (%)) | 9 (14.3) | 6 (17.6) | 0.6622 |
| Antipseudomonal β-lactam (n (%)) | 8 (12.7) | 9 (26.5) | 0.0887 |
| Carbapenem (n (%)) | 4 (6.3) | 10 (29.4) | 0.0020 |
| Blood neutrophils (×109/L, median (SD)) | 7.3 (4.5) | 7.9 (5.1) | 0.5948 |
MDR, multidrug resistance; SD, standard deviation; IQR, interquartile range; ICU, intensive care unit; VAP, ventilator-associated pneumonia.
Other etiologic diagnoses for bronchiectasis include diffuse panbronchiolitis, allergic bronchopulmonary aspergillosis, connective tissue diseases, immune deficiency, ciliary dyskinesia, and other congenital disorders. These diagnoses were assessed according to clinician criteria, based on the required complementary test results.
If no compatible etiologic diagnosis was established, bronchiectasis was classified as idiopathic.
Antibiotic exposures within 90 days of P. aeruginosa isolation.